Published in World J Gastroenterol on January 07, 2017
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Mucosal healing in inflammatory bowel diseases: a systematic review. Gut (2012) 3.02
Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27
Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol (2015) 1.29
Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology (2014) 1.12
Impact of disease location on fecal calprotectin levels in Crohn's disease. Scand J Gastroenterol (2015) 1.12
Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y) (2012) 1.08
Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol (2016) 1.05
Serum trefoil factors in patients with inflammatory bowel disease. Digestion (2006) 0.97
Treatment algorithms in Crohn's - up, down or something else? Best Pract Res Clin Gastroenterol (2014) 0.94
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut (2015) 0.92
Trefoil factors in inflammatory bowel disease. World J Gastroenterol (2014) 0.89
Mucosal healing and deep remission: what does it mean? World J Gastroenterol (2013) 0.87
Serum human trefoil factor 3 is a biomarker for mucosal healing in ulcerative colitis patients with minimal disease activity. J Crohns Colitis (2015) 0.84
Optimizing biologic treatment in IBD: objective measures, but when, how and how often? BMC Gastroenterol (2015) 0.84
Is faecal calprotectin equally useful in all Crohn's disease locations? A prospective, comparative study. Arch Med Sci (2015) 0.82
Disease monitoring in inflammatory bowel disease. World J Gastroenterol (2015) 0.80